Patents by Inventor Robert Jiang
Robert Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250108228Abstract: A system used for conducting transcranial magnetic stimulation (TMS) in a small animal is disclosed. The system may comprise: a miniaturized coil comprising C-shaped magnetic iron core having a first base and a second base, and having insulated copper wires wound around the magnetic iron core; and a stimulator that is configured to generate TMS pulses through the miniaturized coil. A method for conducting transcranial magnetic stimulation (TMS) in a small animal is also disclosed. The method may comprise: placing a miniaturized coil proximate a skull of the small animal, and generating an E-field in a brain of the small animal using the miniaturized coil.Type: ApplicationFiled: September 27, 2024Publication date: April 3, 2025Inventors: Dong Song, Charles Y. Liu, Robert Isenhart, Wenxuan Jiang
-
Publication number: 20250099505Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.Type: ApplicationFiled: September 4, 2024Publication date: March 27, 2025Applicant: Astellas Institute for Regenerative MedicineInventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
-
Publication number: 20250090586Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.Type: ApplicationFiled: July 19, 2024Publication date: March 20, 2025Applicant: Astellas Institute for Regenerative MedicineInventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
-
Publication number: 20250085627Abstract: Organotin patterning compositions can incorporate Sn—F bonds to improve pattering performance. A precursor solution for a radiation patterning composition can comprise a blend of an organic solvent, an organotin composition represented by the formula RSnL3, and a compound capable of generating Sn—F bonds wherein R is a substituted or unsubstituted hydrocarbyl ligand with 1 to 31 carbon atoms and an Sn—C bond and L is a hydrolysable ligand. The fluoride source can be an ammonium fluoride. The patterning structure on a substrate surface has RSnFn moieties, generally within an oxo-hydroxo network.Type: ApplicationFiled: September 11, 2024Publication date: March 13, 2025Inventors: Brian J. Cardineau, Robert E. Jilek, Kai Jiang, Alexander C. Marwitz
-
Publication number: 20250082545Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.Type: ApplicationFiled: November 21, 2024Publication date: March 13, 2025Inventors: Christy Lynn Chapman, Sinue Gomez-Mower, Weirong Jiang, Joseph Michael Matusick, Christie Leigh McCarthy, Connor Thomas O'Malley, John Stephen Peanasky, Shivani Rao Polasani, James Ernest Webb, Michael Clement Ruotolo, JR., Bryan James Musk, Jared Seaman Aaldenberg, Eric Lewis Allington, Douglas Miles Noni, JR., Amber Leigh Tremper, Kristen Dae Waight, Kevin Patrick McNelis, Patrick Joseph Cimo, Steven Edward DeMartino, Robert Anthony Schaut, Adam Robert Sarafian
-
Publication number: 20250074930Abstract: Organotin patterning compositions have radiation sensitive ligands with acetal functional groups. Precursor compositions are compositions comprising (OR4)(OR3)R2CR1SnL3, where the R groups are substituted or unsubstituted hydrocarbyl groups and L is a hydrolysable ligand. The precursors can be formed into coating that can be patterned with radiation, in particular EUV radiation. Coatings formed with blended precursors with hydrocarbyl-based ligands with some having acetal groups and others lacking acetal groups can be particularly effective for improving positive tone patterning.Type: ApplicationFiled: August 27, 2024Publication date: March 6, 2025Inventors: Alexander C. Marwitz, Kai Jiang, Bryan T. Novas, Robert E. Jilek, Christopher J. Reed, Brian J. Cardineau, Munendra Yadav
-
Patent number: 12244337Abstract: This application describes techniques for testing fiber optic telecommunication systems, such as undersea fiber optic cable systems. Testing terminals may be deployed at a location of terminating equipment for a fiber optic cable. The testing terminals may be operated remotely. The testing terminals may be configured to programmatically test the cable by loading one or more tests and automatically configure the cable's transmitters and receivers based on predetermined loading schemes selected based on the tests to be performed. The testing terminals may iterate over channels and fiber pairs of the cable and may use back-to-back tests to remove artifacts from test results. Using the described techniques, a cable's channels and fiber pairs can be fully characterized in the amount of time afforded for a typical testing schedule, which was not generally possible using conventional testing.Type: GrantFiled: August 28, 2021Date of Patent: March 4, 2025Assignee: SubCom, LLCInventors: William W. Patterson, D. Mark Havens, Robert P. Bellomo, Bamdad Bakhshi, Robert Behringer, Roberto Mattos, Ying Jiang, William C. Barnett, Mark Enright
-
Patent number: 12231284Abstract: Methods and apparatus in a fifth-generation wireless communications network, including an example method, in a wireless device, that includes determining a reporting quality threshold for a parameter related to channel state information (CSI); performing a measurement for each of a plurality of beams from a first predetermined set of beams for evaluation; evaluating the measurement for each of the plurality of beams against the reporting quality threshold; discontinuing the performing and evaluating of measurements in response to determining that the reporting quality threshold is met for one of the beams, such that one or more beams in the first predetermined set of beams are not measured and evaluated; and reporting, to the wireless communications network, CSI for the one of the beams.Type: GrantFiled: June 8, 2022Date of Patent: February 18, 2025Assignee: Telefonaktiebolaget LM Ericsson (publ)Inventors: Stefan Parkvall, Janne Peisa, Gunnar Mildh, Robert Baldemair, Stefan Wager, Jonas Kronander, Karl Werner, Richard Abrahamsson, Ismet Aktas, Peter Alriksson, Junaid Ansari, Shehzad Ali Ashraf, Henrik Asplund, Fredrik Athley, Håkan Axelsson, Joakim Axmon, Johan Axnäs, Kumar Balachandran, Gunnar Bark, Jan-Erik Berg, Andreas Bergström, Håkan Björkegren, Nadia Brahmi, Cagatay Capar, Anders Carlsson, Andreas Cedergren, Mikael Coldrey, Icaro L. J. da Silva, Erik Dahlman, Ali El Essaili, Ulrika Engström, Mårten Ericson, Erik Eriksson, Mikael Fallgren, Rui Fan, Gabor Fodor, Pål Frenger, Jonas Fridén, Jonas Fröberg Olsson, Anders Furuskär, Johan Furuskog, Virgile Garcia, Ather Gattami, Fredrik Gunnarsson, Ulf Gustavsson, Bo Hagerman, Fredrik Harrysson, Ning He, Martin Hessler, Kimmo Hiltunen, Songnam Hong, Dennis Hui, Jörg Huschke, Tim Irnich, Sven Jacobsson, Niklas Jaldén, Simon Järmyr, Zhiyuan Jiang, Martin Johansson, Niklas Johansson, Du Ho Kang, Eleftherios Karipidis, Patrik Karlsson, Ali S. Khayrallah, Caner Kilinc, Göran N. Klang, Sara Landström, Christina Larsson, Gen Li, Bo Lincoln, Lars Lindbom, Robert Lindgren, Bengt Lindoff, Fredrik Lindqvist, Jinhua Liu, Thorsten Lohmar, Qianxi Lu, Lars Manholm, Ivana Maric, Jonas Medbo, Qingyu Miao, Reza Moosavi, Walter Müller, Elena Myhre, Johan Nilsson, Karl Norrman, Bengt-Erik Olsson, Torgny Palenius, Sven Petersson, Jose Luis Pradas, Mikael Prytz, Olav Queseth, Pradeepa Ramachandra, Edgar Ramos, Andres Reial, Thomas Rimhagen, Emil Ringh, Patrik Rugeland, Johan Rune, Joachim Sachs, Henrik Sahlin, Vidit Saxena, Nima Seifi, Yngve Selén, Eliane Semaan, Sachin Sharma, Cong Shi, Johan Sköld, Magnus Stattin, Anders Stjernman, Dennis Sundman, Lars Sundström, Miurel Isabel Tercero Vargas, Claes Tidestav, Sibel Tombaz, Johan Torsner, Hugo Tullberg, Jari Vikberg, Peter von Wrycza, Thomas Walldeen, Anders Wallen, Pontus Wallentin, Hai Wang, Ke Wang Helmersson, Jianfeng Wang, Yi-Pin Eric Wang, Niclas Wiberg, Emma Wittenmark, Osman Nuri Can Yilmaz, Ali Zaidi, Zhan Zhang, Zhang Zhang, Yanli Zheng
-
Patent number: 12226370Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.Type: GrantFiled: March 29, 2023Date of Patent: February 18, 2025Assignee: Corning IncorporatedInventors: Christie Leigh McCarthy, Sinue Gomez-Mower, Weirong Jiang, Joseph Michael Matusick, Steven Edward DeMartino, Connor Thomas O'Malley, John Stephen Peanasky, Shivani Rao Polasani, James Ernest Webb, Michael Clement Ruotolo, Jr., Bryan James Musk, Jared Seaman Aaldenberg, Eric Lewis Allington, Douglas Miles Noni, Jr., Amber Leigh Tremper, Kristen Dae Waight, Kevin Patrick McNelis, Patrick Joseph Cimo, Christy Lynn Chapman, Robert Anthony Schaut
-
Patent number: 12225514Abstract: This disclosure describes systems, methods, and devices related to using enhanced high efficiency (HE) frames. A device may determine a high efficiency signal-B (HE-SIG-B) field for a high efficiency (HE) frame, the HE-SIG-B field comprising a common information field and a user information field. The device may determine a data portion of the HE frame, wherein the data portion includes one or more resource units (RUs) with a size equal to a number of tones. The device may determine a first resource allocation subfield and a second resource allocation subfield of the common information field based at least in part on the number of tones. The device may cause to send the HE frame.Type: GrantFiled: January 6, 2021Date of Patent: February 11, 2025Assignee: Intel CorporationInventors: Xiaogang Chen, Feng Jiang, Qinghua Li, Robert Stacey
-
Patent number: 12213115Abstract: This disclosure describes systems, methods, and devices related to using enhanced high efficiency (HE) frames. A device may determine a high efficiency signal-B (HE-SIG-B) field for a high efficiency (HE) frame, the HE-SIG-B field comprising a common information field and a user information field. The device may determine a data portion of the HE frame, wherein the data portion includes one or more resource units (RUs) with a size equal to a number of tones. The device may determine a first resource allocation subfield and a second resource allocation subfield of the common information field based at least in part on the number of tones. The device may cause to send the HE frame.Type: GrantFiled: May 20, 2021Date of Patent: January 28, 2025Assignee: Intel CorporationInventors: Xiaogang Chen, Feng Jiang, Qinghua Li, Robert Stacey
-
Publication number: 20250026700Abstract: An efficient and selective catalyst for the condensed phase hydrogenation of captured CO2 in the presence of an advanced water-lean post combustion capture solvent, EEMPA. Selected heterogenous catalysts for suppress N-methylation of the capture solvent; especially a noble metal on a reducible metal oxide support is highly selective for C—N cleavage to produce methanol.Type: ApplicationFiled: July 18, 2023Publication date: January 23, 2025Inventors: Jotheeswari Kothandaraman, Johnny Saavedra Lopez, Yuan Jiang, Robert A. Dagle, David J. Heldebrant
-
Patent number: 9371329Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: GrantFiled: May 9, 2014Date of Patent: June 21, 2016Assignee: Gilead Sciences, Inc.Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
-
Patent number: 8952034Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: GrantFiled: July 26, 2010Date of Patent: February 10, 2015Assignee: Gilead Sciences, Inc.Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
-
Publication number: 20140303158Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: ApplicationFiled: May 9, 2014Publication date: October 9, 2014Applicant: GILEAD SCIENCES, INC.Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
-
Patent number: 8754103Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: GrantFiled: July 26, 2010Date of Patent: June 17, 2014Assignee: Gilead Sciences, Inc.Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki
-
Patent number: 8716319Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.Type: GrantFiled: February 9, 2010Date of Patent: May 6, 2014Assignee: Gilead Sciences, Inc.Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
-
Patent number: 8389500Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.Type: GrantFiled: October 28, 2009Date of Patent: March 5, 2013Assignee: Gilead Sciences, Inc.Inventors: Matthew Abelman, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Xiaofen Li, Thao Perry, Jeff Zablocki
-
Patent number: 8158810Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.Type: GrantFiled: February 13, 2009Date of Patent: April 17, 2012Assignees: Gilead Sciences, Inc., The Endowment For Research in Human Biology, Inc.Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Robert Jiang, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang, Wing Ming Keung, Guoxin Tao
-
Publication number: 20110021521Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.Type: ApplicationFiled: July 26, 2010Publication date: January 27, 2011Applicant: Gilead Palo Alto, Inc.Inventors: Britton Corkey, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Gregory Notte, Eric Parkhill, Thao Perry, Jeff Zablocki